GGrantIndex
← Search

Nucleic Acid

$226,394P30FY2015CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

PROJECT SUMMARY (See instructions): The OSUCCC Nucleic Acid Shared Resource (NASR) provides services to cancer investigators for DNA sequencing, genotyping, DNA methylation analysis, and quantitative real-time PCR on a variety of instrumentation platforms, as well as access to equipment for nucleic acid purification, quantitative measurement and quality control of nucleic acids, and nucleic acid imaging. NASR services include comprehensive training, consultation and assistance in experimental design and expertise to develop novel methodologies and applications relevant to cancer research. The integration of several technologies into a new multifunctional OSUCCC NASR in 2004 and consolidation of the NASR on the second floor of the Biomedical Research Tower in 2007 promoted interdisciplinary activity, and enhanced cross training of staff increasing their technical skills, motivation and flexibility. These changes resulted in optimal usage of space equipment and expertise, and increased productivity and cost-effectiveness. New equipment for highthroughput gene expression analysis and next-generation sequencing technologies has expanded NASR research capabilities for both genomic and epigenomic support. Highly experienced personnel perform continuous optimization of methods and protocols with outstanding quality control which is crucial for the improvement of data quality and turnaround times. There are strong established interactions with other shared resources including the Microarray, Proteomics and Biomedical Informatics Shared Resources. The NASR maintains a website providing basic information about the policies of the facility and convenient online scheduling and secure data transfer mechanisms. The NASR's specific goals are to: 1) provide reliable, high-quality, affordable, low- and high-throughput, genomic and epigenomic support; 2) provide, optimize, develop and apply early access technologies relevant to cancer research; 3) provide and develop infrastructure and staff for new technologies for cancer research; 4) provide immediate access to data analysis and troubleshooting; 5) provide investigators with training in data analysis, experimental strategies and assistance with investigator publications. Last year's total operational expenses of $1,540,977 were covered by 46.8% charge-backs/other grants, 11.1%i CCSG support and 42.1% institutional support. In the past year, 90.9% of NASR usage was from 96 peer-reviewed funded investigators from all 6 OSUCCC research programs. Building on this solid foundation, the mandate of the OSUCCC NASR is to be an outstanding resource, to provide the best support, and to provide the highest-quality data at the lowest price in a period of rapid and profound technological advances.

View original record on NIH RePORTER →